| dc.creator |
Mnyambwa, N. P. |
|
| dc.creator |
Kim, J. |
|
| dc.creator |
Ngadaya, E. S. |
|
| dc.creator |
Kazwala, R. |
|
| dc.creator |
Petrucka, P. |
|
| dc.creator |
Mfinanga, S. G. |
|
| dc.date |
2017-12-11T06:01:08Z |
|
| dc.date |
2017-12-11T06:01:08Z |
|
| dc.date |
2017 |
|
| dc.date.accessioned |
2022-10-25T08:53:39Z |
|
| dc.date.available |
2022-10-25T08:53:39Z |
|
| dc.identifier |
https://www.suaire.sua.ac.tz/handle/123456789/1864 |
|
| dc.identifier.uri |
http://hdl.handle.net/123456789/93975 |
|
| dc.description |
Evolving novel and/or unfamiliar mutations are revolutionizing the pathways of antibiotic resistance of clinical tuberculosis. The accumulation and interaction of these poorly characterized mutations augment the complexity of resistant pathogenic strains and raise public health concerns. This article reviews our current understanding of the genetic changes that characterize drug resistance in tuberculosis and highlights the imperative for further investigations focusing on the effects of an individual mutation and interacting mutations with detailed strain epidemiology, particularly as these pertain to technologylimited countries with high tuberculosis incidence rates. Concomitantly, there is a need for the development, testing, and uptake of new tools for studying the effects of these mutations in drug resistance and fitness cost of the pathogen. Such genetic data are critical for effective localized and global tuberculosis control interventions and for accurate epidemiological predictions. |
|
| dc.format |
application/pdf |
|
| dc.language |
en |
|
| dc.publisher |
Springer Berlin Heidelberg |
|
| dc.subject |
Clinical implication |
|
| dc.subject |
Novel drug resistance |
|
| dc.subject |
Resistant tuberculosis |
|
| dc.title |
Clinical implication of novel drug resistance-conferring mutations in resistant tuberculosis |
|
| dc.type |
Article |
|